Skip to main content
OpenTrials
Completed

NCT Number: NCT04510675

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PCR Corp

St. Petersburg, Florida, 33702, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Good general health, as assessed by medical history and brief dermal skin examination of the application site (back);
  • Was fully informed of the risks of entering the study and was willing to provide written consent to enter the study;
  • Was willing to follow study rules, which included: no sun exposure (for example; no swimming, sunbathing, or tanning beds), avoided activities that would cause excessive sweating, abstained from use of lotions, creams, or oils on the back area;
  • Was willing to not change current brand of personal care products such as soaps, body washes, laundry detergents, body sprays, body spritzes, etc. while participating on the study;
  • Was willing and able to practice an acceptable measure of contraception (i.e. birth control medication for at least 3 months prior, condom with spermicide or birth control injections,) during the study, if female of childbearing potential. To be considered female of non-childbearing potential, subject must have had a hysterectomy, tubal ligation, or had been post-menopausal for at least 1 year.

Exclusion criteria

  • Clinically significant skin disease which contraindicated participation, including psoriasis, eczema, atopic dermatitis, and active cancer;
  • Asthma that required medication;
  • Insulin-dependent diabetes;
  • Known immunological disorders such as HIV positive, AIDS and systemic lupus
  • erythematosus;
  • Treatment for any type of cancer within the last six months;
  • Routine use (as defined by using more than 3 days in a week) of any anti-inflammatory drug (e.g., aspirin, ibuprofen, corticosteroids; 81 mg aspirin is acceptable), immunosuppressive drugs, antihistamine medication (steroid nose drops and/or eye drops are acceptable) or over-the-counter pain medication that was ingested in quantities exceeding label instructions;
  • Use of topical drugs at patch site;
  • Pregnancy, lactation, or planning a pregnancy (confirmed by a urine pregnancy test administered to females of childbearing potential);
  • Medical condition which, in the Investigator's judgement, made the subject
  • ineligible or placed the subject at undue risk;
  • Participation in any patch test for irritation or sensitization within the last four weeks;
  • Dermatological aberrations in or around test sites which included sunburn, extremely deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or any other disfiguration of the test site;
  • Confirmed allergy to adhesives, bandages, or ingredients in OmezaTM Collagen Matrix;
  • History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax).

Treatment and study plan

Test Article

Device

Omeza Collagen Matrix

Negative Control

Other

Occlusive Patch of 0.9% sodium chloride, NaCl

Primary outcomes

  1. Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix

    Time frame: 24, 48, 72, and 96 Hours

    Erythema is evaluated during the challenge phase based on a numeric scale from 0 - 3 (0: No visible reaction, +: Slight/patchy, 1: Mild, 2: Moderate, 3: Strong). A score of 1, 2, or 3 indicates dermal sensitization.

Secondary outcomes

  1. Adverse Events Deemed Related to the Test Product or the Study

    Time frame: 6 weeks

    The secondary outcome measure is the number of adverse events deemed related to the test article or the study.

Sponsors and collaborators

Lead sponsor

Omeza, LLC

Industry

Registry information

Official study title

A 6-Week, Randomized, Evaluator-Blinded, In Vivo Within Subject Repeat Test to Evaluate the Irritation and Sensitization Potential of Omeza Collagen Matrix in Healthy Volunteers

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Aug 12, 2020
Registry last updated
May 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.